What is Sofosbuvir?

Sofosbuvir is an advanced direct-acting antiviral (DAA) medication categorized as a nucleotide analog NS5B polymerase inhibitor. It represents a landmark breakthrough in hepatology, serving as the core backbone for modern pan-genotypic treatment regimens for chronic Hepatitis C virus (HCV) infection.

Designed to target the central engine of viral replication, Sofosbuvir disrupts the synthesis of viral genetic material. Unlike older interferon-based treatments, Sofosbuvir offers extremely high cure rates, shortened treatment durations, and a favorable systemic safety profile.

What is Sofosbuvir Used For?

Sofosbuvir is prescribed for adult and pediatric patients (typically 3 years of age and older) for the treatment and curative management of chronic Hepatitis C virus (HCV) infection:

• Broad Genotypic Coverage: Effective across HCV Genotypes 1, 2, 3, 4, 5, and 6.
• Combination Therapy Backbone: Administered as part of combination regimens alongside other direct-acting antivirals (such as Velpatasvir, Ledipasvir, or Daclatasvir) with or without Ribavirin.
• Diverse Clinical Profiles: Indicated for patients without cirrhosis, patients with compensated or decompensated cirrhosis, individuals co-infected with HIV-1, and liver transplant recipients.

How Does Sofosbuvir Work?

In host liver cells (hepatocytes), the Hepatitis C virus relies on its NS5B RNA-dependent RNA polymerase enzyme to copy its genetic material. Sofosbuvir operates through a precise molecular mechanism:

• Intracellular Activation: Sofosbuvir is a prodrug that rapidly enters hepatocytes and undergoes intracellular metabolism to form its pharmacologically active uridine analog triphosphate derivative (GS-461203).
• Targeted Kinase Inhibition: The active metabolite competes with natural nucleotides and incorporates directly into the expanding HCV RNA strand via the NS5B polymerase enzyme.
• Chain Termination: Once incorporated, Sofosbuvir acts as a defective building block, causing immediate RNA chain termination. This halts viral replication, rapidly drops circulating HCV viral loads to undetectable levels, and allows the immune system to clear the virus.

Benefits of Sofosbuvir

• High Cure Rates (SVR12): Achieves Sustained Virologic Response (cure) in over 95% of patients across major HCV genotypes when used in appropriate combination regimens.
• High Barrier to Resistance: The active site of the NS5B polymerase is highly conserved across HCV strains, making the development of viral resistance against Sofosbuvir extremely rare.
• Interferon-Free & Well-Tolerated: Replaces historical injectable interferon regimens, avoiding severe side effects like severe depression, flu-like symptoms, and bone marrow suppression.

Available Strengths

Sofosbuvir is manufactured in precise oral strengths as single-agent tablets, as well as formulated within fixed-dose combination (FDC) tablets:

Single-Agent Formulations

• 400 mg film-coated tablets (Standard adult dose)
• 200 mg film-coated tablets or oral pellets (Pediatric formulations)

Common Fixed-Dose Combinations

• Sofosbuvir 400 mg / Velpatasvir 100 mg
• Sofosbuvir 400 mg / Ledipasvir 90 mg
• Sofosbuvir 400 mg / Daclatasvir 60 mg (co-packaged or FDC)

Recommended Dosage & Administration

Sofosbuvir is always administered in combination with other antiviral agents; it is never used as a monotherapy.

Standard Adult Dosage Guidelines

• Standard Daily Dose: One 400 mg tablet taken orally once daily.
• Treatment Duration: Typically 12 to 24 weeks, depending on HCV genotype, baseline cirrhosis status, prior treatment history, and the specific partner antiviral drugs used.

Administration Rules

• With or Without Food: Can be taken with or without meals.
• Swallow Whole: Swallow the tablet whole with a glass of water. Do not crush, split, or chew the tablet (Sofosbuvir has an intensely bitter taste).
• Consistency is Key: Take your daily dose at approximately the same time every day to maintain steady antiviral drug levels in your system.

Missed Dose

• If a dose is missed within 18 hours of the scheduled time, take it as soon as remembered and resume your normal daily schedule. If more than 18 hours have passed, skip the missed dose and resume your regular timing.
Do not take two doses at once.

Common & Serious Side Effects

Sofosbuvir alone is exceptionally well-tolerated. Most observed side effects depend on the co-administered antiviral medications (such as Ribavirin or other DAAs):

• Common Mild Effects: Headache, fatigue/unusual tiredness, nausea, insomnia, and mild dizziness.
• Hepatitis B Reactivation (Boxed Warning): Risk of severe acute flare-up or reactivation of Hepatitis B virus (HBV) in patients co-infected with HBV and HCV. All patients must be screened for active or prior HBV infection before starting therapy.
• Severe Symptomatic Bradycardia: Co-administration of Sofosbuvir with amiodarone (an antiarrhythmic) can cause life-threatening slowing of the heart rate (bradycardia), sometimes requiring pacemaker intervention.
• Hematologic Effects (Regimens with Ribavirin): Hemolytic anemia and reduced red blood cell counts when Ribavirin is included in the treatment schedule.

Drug Interactions

Sofosbuvir is a substrate of the drug transporter P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCR-P):

• P-gp Inducers: Strong P-gp inducers such as rifampin, carbamazepine, St. John’s Wort, oxcarbazepine, and phenytoin significantly decrease Sofosbuvir blood concentrations, leading to loss of therapeutic response and treatment failure. Co-administration is contraindicated.
• Amiodarone: Concomitant use with Sofosbuvir-containing regimens is strongly disadvised due to risks of severe, symptomatic bradycardia.
• Anticonvulsants & Antimycobacterials: Concomitant use with specific seizure or TB medications should be avoided or carefully reviewed by an infectious disease specialist.

Pregnancy and Breastfeeding

• Sofosbuvir Monotherapy / DAA Combinations: Clinical data on pregnant women are limited. Treatment is generally deferred until after delivery unless immediate therapy is clinically necessary.
• Regimens with Ribavirin: If Ribavirin is co-administered with Sofosbuvir, it carries an extreme risk of severe birth defects and embryo-fetal death. Strict double contraception is mandatory for female patients and male partners during treatment and for 6 months post-treatment.
• Breastfeeding: It is unknown whether Sofosbuvir or its active metabolites pass into human breast milk. Consult your treating physician to weigh clinical benefits against potential infant risk.

Monitoring During Treatment

Regular clinical evaluations ensure optimal safety and confirm complete viral clearance:

• HBV Screening: Baseline testing for HBsAg and anti-HBc prior to initiating treatment to assess HBV reactivation risk.
• HCV RNA Quantification: Serum HCV RNA tests at baseline and 12 weeks post-treatment to confirm Sustained Virologic Response (SVR12 = cure).
• Renal & Liver Function Tests: Baseline and periodic monitoring of serum creatinine, eGFR, ALT, AST, and total bilirubin.

Generic Sofosbuvir

Generic formulations of Sofosbuvir are produced globally in compliance with strict international pharmaceutical standards:

• Cost-Effectiveness: Provides an affordable, highly accessible treatment alternative compared to the original brand-name drug (Sovaldi).
• Therapeutic Equivalence: Formulated with the identical active pharmaceutical ingredient (API), delivering bioequivalent viral suppression rates, safety profiles, and cure success.
• Global HCV Elimination: Plays a vital role in global public health initiatives aiming to eradicate Hepatitis C worldwide.

Frequently Asked Questions (FAQs)

Can Sofosbuvir be taken alone without other Hepatitis C drugs?

No. Sofosbuvir must always be combined with at least one other direct-acting antiviral (such as Velpatasvir, Ledipasvir, or Daclatasvir) or Ribavirin. Monotherapy with Sofosbuvir is ineffective and is not approved.

What does "SVR12" mean in Hepatitis C treatment?

SVR12 stands for Sustained Virologic Response at 12 weeks. It means that no Hepatitis C virus is detected in your blood 12 weeks after finishing the full medication course, which indicates that the infection is clinically cured.

Can I drink alcohol while taking Sofosbuvir?

Alcohol should be completely avoided during treatment for Hepatitis C. Alcohol accelerates liver inflammation and damage, counteracting the healing benefits of clearing the virus.

Important Safety Information

This article is intended for educational purposes only and does not substitute for expert medical advice. Always consult a qualified hepatologist, gastroenterologist, or infectious disease specialist before initiating, adjusting, or stopping Hepatitis C therapy.

References

• U.S. Food and Drug Administration (FDA) Prescribing Information (Sovaldi / Sofosbuvir)
• World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Infection
• European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C
• American Association for the Study of Liver Diseases (AASLD) / Infectious Diseases Society of America (IDSA) HCV Guidance

Contact Us

Are you searching for Generic Sofosbuvir, wholesale pricing structures, global availability, or export documentation?

Our expert team is fully equipped to guide you through trusted manufacturer selections, product availability, international licensing, and country-specific import regulations. Contact us today to learn more.

• Sofosbuvir